130 related articles for article (PubMed ID: 11921320)
1. Estimating survival gain for economic evaluations with survival time as principal endpoint: a cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer.
Neymark N; Adriaenssen I; Gorlia T; Caleo S; Bolla M
Health Econ; 2002 Apr; 11(3):233-48. PubMed ID: 11921320
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of the addition of early hormonal therapy in locally advanced prostate cancer: results decisively determined by the cut-off time-point chosen for the analysis.
Neymark N; Adriaenssen I; Gorlia T; Caleo S; Bolla M; Brochon D
Eur J Cancer; 2001 Sep; 37(14):1768-74. PubMed ID: 11549430
[TBL] [Abstract][Full Text] [Related]
3. A cost-outcome analysis of long-term adjuvant goserelin in addition to radiotherapy for locally advanced prostate cancer.
Samant RS; Dunscombe PB; Roberts GH
Urol Oncol; 2003; 21(3):171-7. PubMed ID: 12810202
[TBL] [Abstract][Full Text] [Related]
4. Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer.
Cheng TF; Wang JD; Uen WC
BMC Cancer; 2012 Jan; 12():33. PubMed ID: 22264299
[TBL] [Abstract][Full Text] [Related]
5. Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma.
Konski A; Watkins-Bruner D; Brereton H; Feigenberg S; Hanks G
Cancer; 2006 Jan; 106(1):51-7. PubMed ID: 16323171
[TBL] [Abstract][Full Text] [Related]
6. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
[TBL] [Abstract][Full Text] [Related]
7. Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10).
Konski A; Sherman E; Krahn M; Bremner K; Beck JR; Watkins-Bruner D; Pilepich M
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):788-94. PubMed ID: 16109464
[TBL] [Abstract][Full Text] [Related]
8. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.
Bolla M; Gonzalez D; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Gil T; Collette L; Pierart M
N Engl J Med; 1997 Jul; 337(5):295-300. PubMed ID: 9233866
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy.
Iannazzo S; Pradelli L; Carsi M; Perachino M
Value Health; 2011 Jan; 14(1):80-9. PubMed ID: 21211489
[TBL] [Abstract][Full Text] [Related]
10. Primary hormonal treatment in localized and locally advanced prostate cancer: effectiveness and survival predictive factors.
Utomo NB; Mochtar CA; Umbas R
Acta Med Indones; 2012 Jan; 44(1):10-5. PubMed ID: 22451179
[TBL] [Abstract][Full Text] [Related]
11. Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31.
Souhami L; Bae K; Pilepich M; Sandler H
J Clin Oncol; 2009 May; 27(13):2137-43. PubMed ID: 19307511
[TBL] [Abstract][Full Text] [Related]
12. Goserelin (Zoladex) or orchiectomy in metastatic prostate cancer? A quality of life and cost-effectiveness analysis.
Nygård R; Norum J; Due J
Anticancer Res; 2001; 21(1B):781-8. PubMed ID: 11299844
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer.
Kaisary AV
Prostate Cancer Prostatic Dis; 2005; 8(2):140-51. PubMed ID: 15852051
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer.
Bayoumi AM; Brown AD; Garber AM
J Natl Cancer Inst; 2000 Nov; 92(21):1731-9. PubMed ID: 11058616
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer--the therapeutic challenge of locally advanced disease.
Blasko JC; Lange PH
N Engl J Med; 1997 Jul; 337(5):340-1. PubMed ID: 9233872
[No Abstract] [Full Text] [Related]
16. [Adjuvant or therapeutic androgen suppression in locoregional advanced prostatic carcinoma (RTOG 85-31)].
Hinkelbein W
Strahlenther Onkol; 1998 Jul; 174(7):385-6. PubMed ID: 9689964
[No Abstract] [Full Text] [Related]
17. [Update of the study on survival with early hormonal therapy associated with radiotherapy (EORTC 22863 Study) in patients with advanced prostatic cancer. Interview with Michel Bolla].
Bolla M
Recenti Prog Med; 2001 Feb; 92(2):128-9. PubMed ID: 11294104
[No Abstract] [Full Text] [Related]
18. Radiotherapy in cT3 prostatic carcinoma: retrospective comparison between neoadjuvant and adjuvant hormonotherapy.
Cellini N; Luzi S; Morganti AG; Valentini V; Mantini G; Racioppi M; Smaniotto D; Leone M; Mattiucci GC; Digesù C; Giustacchini M; Destito A; Alcini E
Urol Int; 2004; 72(1):21-7. PubMed ID: 14730161
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer.
Lu L; Peters J; Roome C; Stein K
BJU Int; 2012 Apr; 109(8):1183-92. PubMed ID: 21883830
[TBL] [Abstract][Full Text] [Related]
20. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.
Pilepich MV; Caplan R; Byhardt RW; Lawton CA; Gallagher MJ; Mesic JB; Hanks GE; Coughlin CT; Porter A; Shipley WU; Grignon D
J Clin Oncol; 1997 Mar; 15(3):1013-21. PubMed ID: 9060541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
